Updated on 5 September 2013
Delivering studies on time requires speed in clinical development. Earning the confidence of regulators has been important to start studies on time. Relationship with high recruiting sites, expansion to fast recruiting countries like Germany, Korea, Russia and Thailand has been helpful. Investing in regulatory, medical and expertise in biostatistics also contributes in designing smart protocols with optimal sample size. All these in turn contribute to a swift study.
Regulators in China, Japan and India take six-to-nine months to permit a clinical study, which is six months more as compared to nations like the US, Canada, Western Europe and Australia. In spite of this, these three countries figure in the top five clinical trial destinations due to the importance of the country as a market.
Korea and Australia are also very attractive clinical trial destinations ranking second and fourth respectively. As a market, they rank fifth and twelfth globally. In South East Asia, Singapore and Thailand are presenting themselves as attractive destinations for phase III studies as well as
for early drug development.